Sells injectable neurotoxins and hyaluronic acid gels, including Jeuveau and Evolysse, to licensed aesthetic practitioners.
10-K for FY2025, filed Mar 3, 2026We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the…View ↗
Our current commercially available products and our product candidates represent two of the largest product categories within medical…View ↗
Jeuveau® is a proprietary 900 kilodalton (“kDa”), purified botulinum toxin type A formulation indicated for the temporary improvement in…View ↗
Evolysse™ is a collection of injectable HA gels that utilizes first-generation cold technology. The line includes a variety of products…View ↗
Evolus sells Jeuveau and Evolysse to customers; product sales are tied to customers receiving the goods. In Canada, Jeuveau sales through a distribution partner generate service revenue as the service is performed.
10-K for FY2025, filed Mar 3, 2026The Company generates product revenue from the sales of Jeuveau® and Evolysse™ and service revenue from the sales of Jeuveau® through a…View ↗
For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an…View ↗
For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent…View ↗
10-K for FY2025, filed Mar 3, 2026
FY2025 revenue by product or service ↗$297.2M
10-K for FY2025, filed Mar 3, 2026
$297.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Mar 3, 2026 |
99%
FY2022: 99%
|
Product revenue, net, FY2025
$295M Sources
|
Sold outright |
|
Service revenue
|
0.8%
FY2022: 1.4%
|
Service revenue, FY2025
$2.2M Sources
|
Licensed aesthetic practitioners are its customers; Evolus uses a digital platform to open accounts and tailor purchasing, while Jeuveau sales in Canada go through a distribution partner.
10-K for FY2025, filed Mar 3, 2026We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the…View ↗
Focus on the largest segments of the medical aesthetic market. Aesthetic neurotoxins and injectable HA gels are the largest and two of the…View ↗
Net revenues increased by $30.9 million, or 11.6%, to $297.2 million for the year ended December 31, 2025 from $266.3 million for the year…View ↗
No. It lost $51.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$12.5MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 5, 2026
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises…View ↗
8-K, filed Aug 4, 2026
The Amendment expands the territory covered by the Agreement to include (i) Canada and (ii) Australia and New Zealand combined, and grants…View ↗
8-K, filed Jul 8, 2026
On July 7, 2026, Evolus, Inc. (the “Company”) and IBSA Institut Biochimique SA (“IBSA”) entered into a License, Supply and Distribution…View ↗
Growing. Revenue grew 3.0x in 4 years, from $99.7M in FY2021 to $297.2M in FY2025, about 31% a year.
Added injectable HA gels
The older report described Jeuveau as its first commercial product; the latest report also includes Evolysse injectable HA gels, with products launched in the United States.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 3, 2026Our first commercial product is Jeuveau®, which is a proprietary 900 kilodalton, or kDa, purified botulinum toxin type A formulation…View ↗
Competes with Abbvie, Galderma, Merz, Revance, Hugel, Medytox, Prollenium Medical Technologies, Obagi, Sanofi, Sun Pharma, Johnson & Johnson, and L’Oreal
10-K for FY2025, filed Mar 3, 2026There are only six approved injectable botulinum toxin type A neurotoxins in the United States for aesthetic indications, including…View ↗
Loading...